{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:51:47Z","timestamp":1781614307672,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The 10-valent pneumococcal conjugate vaccine (PCV10) has been offered to all infants through Colombia\u2019s National Immunization Program (NIP) since 2012, with catch-up vaccination until age 5. However, pneumococcal vaccination is not currently included in the NIP for other age groups, such as those\u2009\u2265\u20095 years with medical conditions or older adults. This study assessed the pediatric PCV10 effect on pneumonia mortality rate (MR) trends across different age groups from 2006 to 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective time-series study utilized the national death registration data. Deaths caused by pneumonia as the underlying cause of death were identified via ICD-10 codes and stratified by age groups (&lt;\u20091, 1\u20134, 5\u201317, 18\u201349, 50\u201359, and \u2265\u200960 years). Crude MR, age-adjusted MR, and age-specific MRs per 100,000 population were calculated. Trends were assessed using joinpoint regression and expressed as annual percentage change (APC) and average APC in the pre-PCV10 (2006\u20132011), post-PCV10 (2013\u20132019), early post-PCV10 (2013\u20132016), and late post-PCV10 (2017\u20132019) periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2006 to 2019, there were 102,082 pneumonia-related deaths. The age-specific MR for infants\u2009&lt;\u20091 year significantly decreased from 83.8 to 28.6 per 100,000 between 2006 and 2019 (APC:-6.9), while for children aged 1\u20134 years, it decreased from 9.3 to 3.8 (APC:-5.1). Other older age groups exhibited stable trends in the post-PCV10 period, except for adults aged\u2009\u2265\u200960 years, who had the highest age-specific MR (~\u2009112 per 100,000) over the study period, with an AAPC of 6.5% in the early post-PCV10 period, followed by stable trends in the late post-PCV10 period. The age-adjusted MR showed an increasing trend with an APC of 1.9% from 2008 to 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study found decreasing age-specific MR trends in children under 5 in the post-PCV10 period; however, no evidence of indirect benefits was seen in unvaccinated age groups older than 5 years. The findings underscore the need to expand pneumococcal vaccination programs to other age groups, mainly adults\u2009\u2265\u200960 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-23631-1","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:02:35Z","timestamp":1756710155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing the impact of childhood pneumococcal vaccination on pneumonia mortality in Colombia: a 14-year analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8536-9274","authenticated-orcid":false,"given":"C. I.","family":"Parellada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Urrego-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C.","family":"Pungartnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A C","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"de la Hoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"10258","key":"23631_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204\u201322. https:\/\/doi.org\/10.1016\/s0140-6736(20)30925-9.","journal-title":"Lancet"},{"issue":"11","key":"23631_CR2","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/s1473-3099(22)00510-2","volume":"22","author":"GBD 2019 LRI Collaborators","year":"2022","unstructured":"GBD 2019 LRI Collaborators. Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990\u20132019: results from the global burden of disease study 2019. Lancet Infect Dis. 2022;22(11):1626\u201347. https:\/\/doi.org\/10.1016\/s1473-3099(22)00510-2.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"23631_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/s1473-3099(18)30310-4","volume":"18","author":"GBD 2016 Lower Respiratory Infections Collaborators","year":"2018","unstructured":"GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and National morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis. 2018;18(11):1191\u2013210. https:\/\/doi.org\/10.1016\/s1473-3099(18)30310-4.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"23631_CR4","first-page":"85","volume":"94","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper\u2013February 2019. Wkly Epidemiol Rec. 2019;94(8):85\u2013104.","journal-title":"Wkly Epidemiol Rec"},{"issue":"51","key":"23631_CR5","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.1016\/j.vaccine.2017.10.090","volume":"35","author":"AMM van Deursen","year":"2017","unstructured":"van Deursen AMM, Schurink-Van\u2019t Klooster TM, Man WH, van de Kassteele J, van Gageldonk-Lafeber AB, Bruijning-Verhagen P, et al. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands. Vaccine. 2017;35(51):7107\u201313. https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.090","journal-title":"Vaccine"},{"issue":"4","key":"23631_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/cid\/cix850","volume":"66","author":"DL Luca","year":"2018","unstructured":"Luca DL, Kwong JC, Chu A, Sander B, O\u2019Reilly R, McGeer AJ, et al. Impact of pneumococcal vaccination on pneumonia hospitalizations and related costs in Ontario: A Population-Based ecological study. Clin Infect Dis. 2018;66(4):541\u20137. https:\/\/doi.org\/10.1093\/cid\/cix850","journal-title":"Clin Infect Dis"},{"issue":"2","key":"23631_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/cid\/ciaa614","volume":"73","author":"LH De Oliveira","year":"2021","unstructured":"De Oliveira LH, Shioda K, Valenzuela MT, Janusz CB, Rearte A, Sbarra AN, et al. Declines in pneumonia mortality following the introduction of pneumococcal conjugate vaccines in Latin American and Caribbean countries. Clin Infect Dis. 2021;73(2):306\u201313. https:\/\/doi.org\/10.1093\/cid\/ciaa614","journal-title":"Clin Infect Dis"},{"issue":"9","key":"23631_CR8","doi-asserted-by":"publisher","first-page":"e0184204","DOI":"10.1371\/journal.pone.0184204","volume":"12","author":"AL Andrade","year":"2017","unstructured":"Andrade AL, Afonso ET, Minamisava R, Bierrenbach AL, Cristo EB, Morais-Neto OL, et al. Direct and indirect impact of 10-valent Pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in brazil: A time-series analysis. PLoS ONE. 2017;12(9):e0184204. https:\/\/doi.org\/10.1371\/journal.pone.0184204.","journal-title":"PLoS ONE"},{"issue":"3","key":"23631_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s1473-3099(14)71081-3","volume":"15","author":"MR Moore","year":"2015","unstructured":"Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent Pneumococcal conjugate vaccine in children on invasive Pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301\u20139. https:\/\/doi.org\/10.1016\/s1473-3099(14)71081-3.","journal-title":"Lancet Infect Dis"},{"key":"23631_CR10","doi-asserted-by":"publisher","unstructured":"Rodgers GL, Klugman KP. Surveillance of the impact of pneumococcal conjugate vaccines in developing countries. Hum Vaccin Immunother. 2016;12(2):417\u201320. https:\/\/doi.org\/10.1080\/21645515.2015.1057671.","DOI":"10.1080\/21645515.2015.1057671"},{"issue":"22","key":"23631_CR11","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.vaccine.2017.04.032","volume":"35","author":"G Tsaban","year":"2017","unstructured":"Tsaban G, Ben-Shimol S. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature. Vaccine. 2017;35(22):2882\u201391. https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.032","journal-title":"Vaccine"},{"issue":"2","key":"23631_CR12","doi-asserted-by":"publisher","first-page":"e1003537","DOI":"10.1371\/journal.pmed.1003537","volume":"18","author":"J Kleynhans","year":"2021","unstructured":"Kleynhans J, Tempia S, Shioda K, von Gottberg A, Weinberger DM, Cohen C. Estimated impact of the Pneumococcal conjugate vaccine on pneumonia mortality in South Africa, 1999 through 2016: an ecological modelling study. PLoS Med. 2021;18(2):e1003537. https:\/\/doi.org\/10.1371\/journal.pmed.1003537","journal-title":"PLoS Med"},{"key":"23631_CR13","doi-asserted-by":"publisher","unstructured":"Loo JD, Conklin L, Fleming-Dutra KE, Knoll MD, Park DE, Kirk J et al. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J. 2014;33(Suppl 2):S161-71. https:\/\/doi.org\/10.1097\/inf.0000000000000084","DOI":"10.1097\/inf.0000000000000084"},{"issue":"11","key":"23631_CR14","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/j.vaccine.2020.01.084","volume":"38","author":"P Camargos","year":"2020","unstructured":"Camargos P, Nascimento-Carvalho CM, Teixeira R, Fran\u00e7a E. Lower respiratory infections mortality among Brazilians under-five before and after National Pneumococcal conjugate vaccine implementation. Vaccine. 2020;38(11):2559\u201365. https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.084.","journal-title":"Vaccine"},{"issue":"4","key":"23631_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/21645515.2020.1805990","volume":"17","author":"G Carrasquilla","year":"2021","unstructured":"Carrasquilla G, Porras-Ram\u00edrez A, Martinez S, DeAntonio R, Devadiga R, Talarico C, et al. Trends in all-cause pneumonia and otitis media in children aged\u2009<\u20092 years following pneumococcal conjugate vaccine introduction in Colombia. Hum Vaccin Immunother. 2021;17(4):1173\u201380. https:\/\/doi.org\/10.1080\/21645515.2020.1805990","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"23631_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/jgid.jgid_125_19","volume":"12","author":"R Jimbo-Sotomayor","year":"2020","unstructured":"Jimbo-Sotomayor R, Armijos-Acurio L, Proano-Espinosa J, Segarra-Galarza K, Sanchez-Choez X. Morbidity and mortality due to pneumococcal disease in children in Ecuador from 2005 to 2015. J Global Infect Dis. 2020;12(3):124\u20138. https:\/\/doi.org\/10.4103\/jgid.jgid_125_19","journal-title":"J Global Infect Dis"},{"issue":"4","key":"23631_CR17","doi-asserted-by":"publisher","first-page":"e768","DOI":"10.1093\/infdis\/jiae144","volume":"230","author":"O Prunas","year":"2024","unstructured":"Prunas O, Shioda K, Toscano CM, Bastias M, Valenzuela-Bravo MT, Tito JD, et al. Estimated Population-Level impact of Pneumococcal conjugate vaccines against All-Cause pneumonia mortality among unvaccinated in 5 Latin American countries. J Infect Dis. 2024;230(4):e768\u201376. https:\/\/doi.org\/10.1093\/infdis\/jiae144.","journal-title":"J Infect Dis"},{"key":"23631_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.22354\/24223794.1165","volume":"28","author":"C Torres-Mart\u00ednez","year":"2024","unstructured":"Torres-Mart\u00ednez C, Camacho-Moreno G, Pati\u00f1o-Ni\u00f1o J, Coronell W, Leal AL, G\u00e1mez G. Pneumococcal diseases in colombia: epidemiological analysis before and during the universal children immunization against Streptococcus pneumoniae in the light of a vaccine change in 2022. Infectio. 2024;28:33\u201344.","journal-title":"Infectio"},{"key":"23631_CR19","unstructured":"World Health Organization. Immunization data. Available from: https:\/\/immunizationdata.who.int\/global?topic=&location=. Cited 2024 Sep 07."},{"key":"23631_CR20","unstructured":"Secretaria de Salud Colombia. Esquema Nacional de Vacunaci\u00f3n Colombia 2024. Available from: https:\/\/cesar.gov.co\/d\/images\/boletines\/2024\/0055\/esquema_de_vacunacion_2024.pdf. Cited 2024 Sep 07."},{"key":"23631_CR21","unstructured":"Departamento Administrativo Nacional de Estad\u00edstica (DANE). Microdatos. Available from: http:\/\/microdatos.dane.gov.co\/index.php\/catalog\/MICRODATOS\/about_collection Cited 2024 Sep 09."},{"key":"23631_CR22","unstructured":"World Health Organization. Age standardization of rates: a new WHO standard. GPE Discussion Paper Series: No. 31. Geneva: World Health Organization. 2001. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/gho-documents\/global-health-estimates\/gpe_discussion_paper_series_paper31_2001_age_standardization_rates.pdf. April 25, 2025."},{"key":"23631_CR23","unstructured":"National Cancer Institute. Joinpoint Regression Program, Version 5.3.0 2025. Available from: https:\/\/surveillance.cancer.gov\/joinpoint\/. May 11, 2025."},{"issue":"3","key":"23631_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11698-018-0181-5","volume":"13","author":"J Jaramillo-Echeverri","year":"2019","unstructured":"Jaramillo-Echeverri J, Meisel-Roca A, Ram\u00edrez-Giraldo MT. More than 100 years of improvements in living standards: the case of Colombia. Cliometrica. 2019;13(3):323\u201366. https:\/\/doi.org\/10.1007\/s11698-018-0181-5.","journal-title":"Cliometrica"},{"key":"23631_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-2296-13-84","volume":"13","author":"PA Mosquera","year":"2012","unstructured":"Mosquera PA, Hern\u00e1ndez J, Vega R, Mart\u00ednez J, Labonte R, Sanders D, et al. Primary health care contribution to improve health outcomes in Bogota-Colombia: a longitudinal ecological analysis. BMC Fam Pract. 2012;13:84. https:\/\/doi.org\/10.1186\/1471-2296-13-84.","journal-title":"BMC Fam Pract"},{"issue":"2","key":"23631_CR26","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/S2214-109X(18)30455-8","volume":"7","author":"C Schuck-Paim","year":"2019","unstructured":"Schuck-Paim C, Taylor RJ, Alonso WJ, Weinberger DM, Simonsen L. Effect of Pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in brazil: a retrospective observational study. Lancet Global Health. 2019;7(2):e249\u201356. https:\/\/doi.org\/10.1016\/S2214-109X(18)30455-8.","journal-title":"Lancet Global Health"},{"key":"23631_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.12688\/gatesopenres.13187.1","volume":"4","author":"K Shioda","year":"2020","unstructured":"Shioda K, Toscano CM, Valenzuela MT, Huarcaya WV, Warren JL, Weinberger DM, et al. Impact of Pneumococcal conjugate vaccine uptake on childhood pneumonia mortality across income levels in Brazil, Colombia, and Peru. Gates Open Res. 2020;4:136. https:\/\/doi.org\/10.12688\/gatesopenres.13187.1","journal-title":"Gates Open Res"},{"issue":"1","key":"23631_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/cid\/ciy872","volume":"69","author":"NK Vadlamudi","year":"2019","unstructured":"Vadlamudi NK, Chen A, Marra F. Impact of the 13-Valent Pneumococcal conjugate vaccine among adults: A systematic review and Meta-analysis. Clin Infect Dis. 2019;69(1):34\u201349. https:\/\/doi.org\/10.1093\/cid\/ciy872.","journal-title":"Clin Infect Dis"},{"key":"23631_CR29","doi-asserted-by":"publisher","unstructured":"Camacho-Moreno G, Leal AL, Pati\u00f1o-Ni\u00f1o J, Vasquez-Hoyos P, Guti\u00e9rrez I, Beltr\u00e1n S, et al. Serotype distribution, clinical characteristics, and antimicrobial resistance of pediatric invasive pneumococcal disease in Colombia during PCV10 mass vaccination (2017\u20132022). Front Med (Lausanne). 2024;22(1380125). https:\/\/doi.org\/10.3389\/fmed.2024.1380125","DOI":"10.3389\/fmed.2024.1380125"},{"key":"23631_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijid.2021.02.031","volume":"105","author":"DF Severiche-Bueno","year":"2021","unstructured":"Severiche-Bueno DF, Severiche-Bueno DF, Bastidas A, Caceres EL, Silva E, Lozada J, et al. Burden of invasive pneumococcal disease (IPD) over a 10-year period in Bogot\u00e1, Colombia. Int J Infect Dis. 2021;105:32\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2021.02.031","journal-title":"Int J Infect Dis"},{"key":"23631_CR31","unstructured":"World Bank. Integrated People-Centred Care for an Aging Population: Colombia case study 2023. Available from: https:\/\/documents1.worldbank.org\/curated\/en\/099638503072441223\/pdf\/IDU176ea19741b0d1140191971a15b9dcde2c50b.pdf. May 15, 2024."},{"issue":"3","key":"23631_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s2352-4642(23)00328-0","volume":"8","author":"S Mahtab","year":"2024","unstructured":"Mahtab S, Blau DM, Madewell ZJ, Ogbuanu I, Ojulong J, Lako S, et al. Post-mortem investigation of deaths due to pneumonia in children aged 1\u201359 months in sub-Saharan Africa and South Asia from 2016 to 2022: an observational study. Lancet Child Adolesc Health. 2024;8(3):201\u201313. https:\/\/doi.org\/10.1016\/s2352-4642(23)00328-0.","journal-title":"Lancet Child Adolesc Health"},{"issue":"10369","key":"23631_CR33","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/s0140-6736(22)02185-7","volume":"400","author":"GBD 2019 Antimicrobial Resistance Collaborators","year":"2022","unstructured":"GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2022;400(10369):2221\u201348. https:\/\/doi.org\/10.1016\/s0140-6736(22)02185-7.","journal-title":"Lancet"},{"key":"23631_CR34","unstructured":"World Health Organization. Global Health Estimates: Methods and Data Sources for Country-Level Causes of Death (2000\u20132019). Available from: https:\/\/www.who.int\/docs\/default-source\/gho-documents\/global-health-estimates\/ghe2019_cod_methods.pdf. May 14, 2025."},{"issue":"3","key":"23631_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.35509\/01239015.828","volume":"26","author":"R Cendales","year":"2022","unstructured":"Cendales R, Pardo C. Calidad de la certificaci\u00f3n de la mortalidad en Colombia, 1997\u20132016. Rev Colomb Cancerol. 2022;26(3):326\u201336. https:\/\/doi.org\/10.35509\/01239015.828","journal-title":"Rev Colomb Cancerol"},{"issue":"1","key":"23631_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.25100\/cm.v49i1.3155","volume":"49","author":"R Cendales","year":"2018","unstructured":"Cendales R, Pardo C. Quality of death certification in Colombia. Colomb Med (Cali). 2018;49(1):121\u20137. https:\/\/doi.org\/10.25100\/cm.v49i1.3155.","journal-title":"Colomb Med (Cali)"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23631-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-23631-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23631-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:54:42Z","timestamp":1781610882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-23631-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23631"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-23631-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. All data used in this study were obtained from publicly accessible, structured databases containing anonymized and aggregated data. These data comply with Resolution 1409 of 2022, issued by the Ministry of Health and Social Protection of Colombia, which permits the secondary use of anonymized data without ethics committee approval for scientific research or public policy formulation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Cintia Irene Parellada and Paula Cristina Pungartnik are employees of MSD Brazil, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. Juan Camilo Urrego and Monica Rojas are employees of MSD Colombia, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA; Fernando de la Hoz has declared no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper; Luis Felipe Reyes has received honoraria for lectures, presentations, educational events and support for attending meetings and\/or travel from Pfizer, MSD, GSK and JJ; Jessica Webster participated in a paid internship of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Angelica Carreira dos Santos is an employee of IQVIA Brazil, which was contracted by Merck & Co., Inc., Rahway, NJ, USA to conduct the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2990"}}